The stock of Cellectis SA (ADR) (NASDAQ:CLLS) is a huge mover today! About 125,176 shares traded hands or 31.42% up from the average. Cellectis SA (ADR) (NASDAQ:CLLS) has declined 33.83% since April 14, 2016 and is downtrending. It has underperformed by 38.51% the S&P500.
The move comes after 8 months positive chart setup for the $723.87M company. It was reported on Nov, 16 by Barchart.com. We have $30.28 PT which if reached, will make NASDAQ:CLLS worth $340.22 million more.
According to Zacks Investment Research, “Cellectis SA is a gene-editing company. The company focused on developing immunotherapies based on gene edited engineered CAR-T cells. Cellectis SA is based in Paris, France.”
More important recent Cellectis SA (ADR) (NASDAQ:CLLS) news were published by: Marketwatch.com which released: “Plus the latest data from Realtor.com on 21 home markets across the US” on March 25, 2015, also Quotes.Wsj.com published article titled: “DOW JONES, A NEWS CORP COMPANY”, Schaeffersresearch.com published: “Cellectis SA (CLLS) Defies Sector Headwinds on Cancer Breakthrough” on May 06, 2016. More interesting news about Cellectis SA (ADR) (NASDAQ:CLLS) was released by: Bidnessetc.com and their article: “Pfizer Inc. Interested In Acquiring French Biotech Firm Cellectis SA (ADR …” with publication date: June 01, 2015.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.